Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Luque, M; Morales-Gallego, M; Sanz-Alvarez, M; Arguiñano, C; Rangel, Y; Ramirez-Merino, N; Qin, MJ; Rovira, A; Albanell, J; Madoz-Gúrpide, J; Rojo, F.

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer

NEOPLASIA. 2026; 78: [doi:10.1016/j.neo.2026.101318]

Aguilar, A; Cobo, M; Calles, A; Azkarate, A; Gonzalez-Cao, M; Molina-Vila, MA; Rosell, R.

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer

LUNG CANCER. 2026; 217: [doi:10.1016/j.lungcan.2026.109461]

Di Grazia, G; Di Lauro, V; Morchón-Araujo, D; Nucera, S; Figuero-Pérez, L; Calleja-Holgado, FJ; Sánchez, DP; Wallbaum, B; Vargas, PR; Palleschi, M; Musolino, A; Cobos, GZ; Paradís, AL; Barroso, G; Cano, OC; Portulas, ED; Caltavituro, A; Buono, G; Gillaranz, YJ; Echavarría, I; López-Tarruella, S; Sirvén, MB; Martínez-Sáez, O; Adamo, B; Mateu, MM; Arpino, G; Bayona, RS; De Laurentiis, M; Rodríguez, CA; Pascual, T; Losada, MV; Schettini, F.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching

EUROPEAN JOURNAL OF CANCER. 2026; 242: [doi:10.1016/j.ejca.2026.116818]

Dieras V; Curigliano G; Martin M; Lerebours F; Tsurutani J; Savard MF; Jerzak KJ; Hu X; Martins de Aquino Pimentel LC; O'Sullivan CC; Tokunaga E; Okines A; Huang CS; Jacot W; Sohn J; Cronemberger Silva E; Mueller V; Yang S; Granata G; Shen Q; Santarpia L; Hamilton E.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(17): 1597-1607 Nº de citas: 9 [doi:10.1200/JCO-25-02600]

Torres-Jiménez, J; Fuentes, JDB; Morales, MG; Ozores, PP; Ruiz-Casado, AI; Vieito, M; Serrano-Gómez, C; Esteban-Villarrubia, J; Calvo, A; Garralda, E; Moreno, V; Corbacho, JG; Martin-Liberal, J; Sarrió, RG.

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04428-z]

Fakih, M; Gill, S; Sampat, K; Chan, DL; Fisher, G; Cruz-Correa, M; Lenz, HJ; Garcia-Alfonso, P; Forget, F; Lonardi, S; Krauss, J; Chen, E; Gracian, AC; Liu, Y; van Buuren, N; Shao, J; Dong, M; Chen, A; Tejani, M; Hecht, JR.

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

ESMO Gastrointestinal Oncology. 2026; 12: [doi:10.1016/j.esmogo.2026.100324]

Motzer, RJ; Albiges, L; Aguirre, SAT; Kanesvaran, R; Centkowski, P; Reimers, MA; Sade, JP; Pouessel, D; Biscaldi, E; Esteban, E; Arija, JAA; Tykodi, SS; Losio, MV; Dighe, A; Ma, H; Valmeekam, V; Simmons, A; Scheffold, C; Andrianova, S; Braun, DA; Powles, T; Choueiri, TK.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

ANNALS OF ONCOLOGY. 2026; 37(6): 861-871 Nº de citas: 2 [doi:10.1016/j.annonc.2026.02.011]

Peters, S; Tan, DSW; Gerber, DE; Urbanic, J; Ramalingam, S; Yu, JM; Xing, LG; Rittmeyer, A; Ciuleanu, TE; de Menezes, J; Kim, HR; Rojas, C; Syrigos, K; Hayashi, H; Haridass, A; Cortinovis, D; Bruno, D; Kimmich, M; Calles, A; Nathani, R; Pudussery, G; Yang, LY; De Ruysscher, D.

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

Nature Cancer. 2026; : [doi:10.1038/s43018-026-01161-y]

García-Campelo, MR; Corral, J; Moreno, F; Munoz, A; Balea, JM; Barragán, B; Ginés, J; Nicolás, FG; Sangro, B; Martin-Sánchez, EM; Trapero-Bertran, M.

Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04323-7]

Pena-Burgos, EM; Suárez-González, J; Muñoz, LH; Valles, MA; Asencio, JM; Mora-Díaz, R; Pozo-Kreilinger, JJ.

STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms

VIRCHOWS ARCHIV. 2026; : [doi:10.1007/s00428-026-04551-w]

Gonzalez, JA; Sebio, A; Martin-Broto, J; Hindi, N; Villarejo-Campos, P; Jiménez, M; Díaz-Beveridge, R; Castellanos, JFO; Andújar, RL; Álvarez, RÁ; Asencio, JM; Serrano, C; Conde, NR; Boix, SC; Krauel, L; Codina, HC; García, JAT; de Llanos, EL; Ninou, AH; Campos, AP; Gruber, AK; Pousa, AL.

First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas

ANNALS OF SURGICAL ONCOLOGY. 2026; : Nº de citas: 1 [doi:10.1245/s10434-026-19487-3]

Lominchar, PL; Díaz-Cambronero, Ó; Muñoz-Muñoz, P; Fernández-Candela, A; Hernández-Sánchez, P; Javaloyes, N; Olivares, V; Rodrigues, CC; Nieto, IP; Díaz-Gómez, D; Ibañez, CB; Pinto, P; Marrero-Marrero, P; López, M; Vallejo, I; Sanz, MC; Videira, F; Martins, P; Orbis, P; Rubio, A; Valderrama, SO; Bermúdez, F; Álvarez, R; Roland, CL; Lyu, H; Clarke, CN; Muñoz-Casares, C; Asencio, JM; Vasques, H.

Consensus Guidelines on Perioperative Care in Primary Retroperitoneal Sarcoma Surgery

ANNALS OF SURGICAL ONCOLOGY. 2026; 33(7): 6881-6909 Nº de citas: 1 [doi:10.1245/s10434-026-19520-5]

Rojo, F; Felip, E; Vidal, OJ; Campelo, RG; Bujanda, DA; Pons, JT; López-Castro, R; Calles, A; Lario, AP; Caro, RB; Aranda, IB; García-Palacios, L; Carpeño, JD.

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Medicine. 2026; 15(4): [doi:10.1002/cam4.71790]

Garcia-Carbonero, R; Benavent, M; Jimenez-Fonseca, P; Alonso-Gordoa, T; Teulé, A; Custodio, A; Tafuto, S; La Casta, A; Spada, F; López, C; Ibrahim, T; Iranzo, V; García-Alfonso, P; González-Flores, E; Silva, MJV; Grande, E; Panzuto, F; Crespo, G; Navarro, M; Castellano, D; Hernando, J; Morales-Herrero, R; Alvarez, GI; Soldevilla, B; Capdevila, J.

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)

JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(9): 774-786 Nº de citas: 2 [doi:10.1200/JCO-25-01808]

Martín M; Guerrero-Zotano AL; Pérez-López ME; Ruiz-Borrego M; Martinez Jañez N; Chacón JI; Gil-Gil M; Andrés R; Bermejo B; Sánchez-Rovira P; Del Barco S; Ponce JJ; Fernandez I; Martínez de Dueñas E; Hinojo-Gonzále C; González M; García-Garre E; Hernando B; de la Haba-Rodriguez J; Álvarez IM; González-Santiago S; Garcia-Saenz JA; Santaballa A; Casas M; Bezares S; Caballero R; Rojo F; Alba E.

Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

CLINICAL CANCER RESEARCH. 2026; 32(5): 850-858 Nº de citas: 1 [doi:10.1158/1078-0432.CCR-25-2435]

Martinez-Lago, N; Cousillas, A; Jara, P; Reboredo, M; Villarroel, PG; Covela, M; Jimeno, R; Agraso, S; Sampedro, P; Carral, A; Perez, M; Garrido, A; Gómez, JD; Alvarez, ND; Fernandez-Montes, A; Lopez, C.

Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study

ESMO Real World Data and Digital Oncology. 2026; 11: [doi:10.1016/j.esmorw.2025.100676]

Fong PC; Kwiatkowski M; Mosca A; Valderrama BP; Li C; Huang YH; Zedan AH; Kuc K; Wiechno P; Laguerre B; Gonzalez-Billalabeitia E; Osipov M; Sener Dede D; Goh JC; Daugaard G; Zhu P; Imai K; Liu Y; Arranz Arija JA.

Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort G.

European Urology Focus. 2026; 12(2): 168-173 [doi:10.1016/j.euf.2025.07.018]

van Aken, ESM; O'Cathail, SM; Gandhi, AK; Bussink, J; Castelo-Branco, L; Eriksen, JG; Argilés, G; Hiley, CT; Atkinson, V; Kazmierska, J; Calles, A; Konopa, K; Le Rhun, E; McDonald, F; Mountzios, G; Putora, PM; Muoio, B; Ricardi, U; Westphalen, CB; Wrona, A; Boot, P; Pentheroudakis, G; Belka, C; Lordick, F; Marijnen, CAM; Martins-Branco, D; De Ruysscher, D; Barriuso, J; Devnani, B; de Jong, MC; Prelaj, A.

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors

ESMO Open. 2026; 11(3): [doi:10.1016/j.esmoop.2026.106076]